Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma

Naohiro Nishida, Makoto Yamsaki, Kazuki Odagiri, Kotaro Yamashita, Koji Tanaka, Daisuke Sakai, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Taroh Satoh, Masaki Mori, Yuichiro Doki

研究成果: ジャーナルへの寄稿記事

抄録

Background/Aim: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. Patients and Methods: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. Results: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). Conclusion: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.

元の言語英語
ページ(範囲)2249-2254
ページ数6
ジャーナルIn Vivo
33
発行部数6
DOI
出版物ステータス出版済み - 1 1 2019

Fingerprint

oxaliplatin
Levoleucovorin
Leucovorin
Disease control
Toxicity
Therapeutics
Peripheral Nervous System Diseases
Appetite
Intravenous Infusions
Disease-Free Survival
Appointments and Schedules
Esophageal Squamous Cell Carcinoma
Epithelial Cells
Safety
Recurrence

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

これを引用

Nishida, N., Yamsaki, M., Odagiri, K., Yamashita, K., Tanaka, K., Sakai, D., ... Doki, Y. (2019). Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma. In Vivo, 33(6), 2249-2254. https://doi.org/10.21873/invivo.11730

Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma. / Nishida, Naohiro; Yamsaki, Makoto; Odagiri, Kazuki; Yamashita, Kotaro; Tanaka, Koji; Sakai, Daisuke; Makino, Tomoki; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Satoh, Taroh; Mori, Masaki; Doki, Yuichiro.

:: In Vivo, 巻 33, 番号 6, 01.01.2019, p. 2249-2254.

研究成果: ジャーナルへの寄稿記事

Nishida, N, Yamsaki, M, Odagiri, K, Yamashita, K, Tanaka, K, Sakai, D, Makino, T, Takahashi, T, Kurokawa, Y, Satoh, T, Mori, M & Doki, Y 2019, 'Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma', In Vivo, 巻. 33, 番号 6, pp. 2249-2254. https://doi.org/10.21873/invivo.11730
Nishida, Naohiro ; Yamsaki, Makoto ; Odagiri, Kazuki ; Yamashita, Kotaro ; Tanaka, Koji ; Sakai, Daisuke ; Makino, Tomoki ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Satoh, Taroh ; Mori, Masaki ; Doki, Yuichiro. / Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma. :: In Vivo. 2019 ; 巻 33, 番号 6. pp. 2249-2254.
@article{fe9f07fc6eeb4bef8699c60a8eade2ee,
title = "Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma",
abstract = "Background/Aim: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. Patients and Methods: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. Results: Of the eight patients with measurable lesions, two patients with partial response (25{\%}) and two with stable disease (25{\%}) were observed. Disease control rate was 50{\%}. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60{\%}), decreased appetite (50{\%}), peripheral sensory neuropathy (40{\%}). Conclusion: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.",
author = "Naohiro Nishida and Makoto Yamsaki and Kazuki Odagiri and Kotaro Yamashita and Koji Tanaka and Daisuke Sakai and Tomoki Makino and Tsuyoshi Takahashi and Yukinori Kurokawa and Taroh Satoh and Masaki Mori and Yuichiro Doki",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/invivo.11730",
language = "English",
volume = "33",
pages = "2249--2254",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Combination therapy with S-1, oxaliplatin and leucovorin in patients with advanced esophageal squamous cell carcinoma

AU - Nishida, Naohiro

AU - Yamsaki, Makoto

AU - Odagiri, Kazuki

AU - Yamashita, Kotaro

AU - Tanaka, Koji

AU - Sakai, Daisuke

AU - Makino, Tomoki

AU - Takahashi, Tsuyoshi

AU - Kurokawa, Yukinori

AU - Satoh, Taroh

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aim: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. Patients and Methods: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. Results: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). Conclusion: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.

AB - Background/Aim: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. Patients and Methods: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. Results: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). Conclusion: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.

UR - http://www.scopus.com/inward/record.url?scp=85074215118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074215118&partnerID=8YFLogxK

U2 - 10.21873/invivo.11730

DO - 10.21873/invivo.11730

M3 - Article

C2 - 31662564

AN - SCOPUS:85074215118

VL - 33

SP - 2249

EP - 2254

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 6

ER -